Dr James Evans, one of SMTL's health services researchers, has recently had a paper published in Applied Health Economics and Health Policy ("Thopaz+ Portable Digital System for Managing Chest Drains: A NICE Medical Technology Guidance", Evans, J.M., Ray, A., Dale, M. et al. Appl Health Econ Health Policy (2019)).
The work, undertaken when James was working for CEDAR, assessed the clinical evidence for Thopaz+, and showed shorter drainage times and length of hospital stay, lower rates of chest drain re-insertion and higher rates of patient satisfaction when used in patients following pulmonary resection compared to conventional chest drainage. One comparative study of the use of Thopaz+ in patients with spontaneous pneumothorax was identified and showed shorter drainage times and length of hospital stay compared to conventional drainage.
The authors concluded that the use of Thopaz+ in patients following pulmonary resection and patients with pneumothorax led to cost savings compared to conventional drainage. The main driver for cost savings was a reduction in length of hospital stay.